Initiation of opiate addiction in a Canadian prison: a case report
© Wood et al; licensee BioMed Central Ltd. 2006
Received: 02 March 2006
Accepted: 16 March 2006
Published: 16 March 2006
In North America, the harms of illicit drug use have been responded to primarily through law enforcement interventions. This strategy has resulted in record populations of addicted individuals being incarcerated in both Canada and the United States. The incarceration of non-violent drug offenders has become increasingly controversial as studies demonstrate the harms, including elevated HIV risk behavior, of incarcerating injection drug users. Other harms, such as the initiation of illicit drug use by prison inmates who previously did not use drugs, have been less commonly described.
We report on the case of an individual who initiated non-injection opiate use in a Canadian prison and developed an addiction to the drug. Upon release into the community, the individual continued using opiates and sought treatment at a clinic. The patient feared that he might initiate injection use of opiates if his cravings could not be controlled. The patient was placed on methadone maintenance therapy.
While anecdotal reports indicate that initiation in prison of the use of addictive illicit substances is frequent, documentation through clinical experience is rare, and the public health implications of this behavior have not been given sufficient attention in the literature. Strategies of incarcerating non-violent drug offenders and attempting to keep illicit drugs out of prisons have not reduced the harms and costs of illicit drug use. Effective, practical alternatives are urgently needed; expanded community diversion programs for non-violent drug offenders deserve particular attention.
In North America, policy-makers have primarily responded to the public health emergency among injection drug users (IDU) by allocating resources to criminal justice interventions. The reliance on law enforcement has resulted in record incarceration rates in the United States and Canada.  The incarceration of illicit drug users also has major implications for public health because of the potential for infectious disease transmission in prison. [2–5] This may be of particular concern for human immunodeficiency virus (HIV) transmission, which has been previously documented among inmates in a Scottish prison [4, 6] and suspected in several other settings as a result of syringe sharing between incarcerated injection drug users. [7–9]
The concentration of addicted individuals within prisons is believed to result in elevated HIV risk behavior because incarcerated IDU generally have high rates of HIV and HCV, and the interventions that are available in the community, such as well managed agonist detoxification and maintenance treatment and needle exchange, are often not available in prison.  In addition to syringe sharing, there are a number of other potential harms of mixing addicted populations with other inmates. Here, we report on a case of an opiate-addicted individual seeking methadone maintenance therapy (MMT) in the community soon after his release from a Canadian prison.
A 20-year-old white male was seen as an outpatient at an addiction medicine clinic in Calgary, Canada. The male reported alcohol and cocaine use prior to being arrested, and the patient acknowledged that chaotic behavior related to the use of these substances had contributed to his crimes and eventual incarceration. While incarcerated, the individual reported initiating use of illicit (prescription) opiates, and his preferred route of administration was via nasal inhalation. Although the patient reported that his fellow inmates had frequently injected (he even reported assisting with injections), the patient denied injection use of illicit drugs in prison. The patient reported experiencing severe physical withdrawal symptoms during periods of non-opiate use in prison and soon became a regular user.
Upon release into the community, the patient reported that he had continued his xuse of diverted pharmaceutical opiates and that he had developed a pattern of use consistent with severe physical addiction. At the time of presentation at the clinic, the patient's urine tested positive for opiates. At that time, the patient reported that his unstable condition was such that he feared he might initiate intravenous opiate injection use if he did not do something to control his opiate cravings. The patient did not say why he had not injected opiates in prison but reported recognizing that injection opiate use would represent a further negative progression of his opiate addiction. After some discussion, the patient was started on methadone maintenance therapy, 10 mg per day, increasing 10 mg per day until desired therapeutic effect was reached.
We have described a case of an individual initiating opiate addiction in a Canadian prison. With respect to this issue, it is important to stress that initiation of the use of addictive illicit substances while incarcerated has been previously reported. For instance, one study reported that 20% of IDU surveyed initiated injection drug use in prison.  However, while this is believed to occur frequently (from anecdotal reports), it is rarely documented through clinical experience. Accordingly, the public health and social implications of initiation of illicit drug addiction in prison have not received significant attention in the literature. This is of concern, since this issue has major implications for both prison and community health.
To date, the principal strategy to address initiation of illicit drug use in prison has been to redouble efforts to keep illicit drugs out of the prisons, though correction officials concede that this is almost impossible. However, over the last several decades, experience has proven that more pragmatic solutions are available and can be effective. [10, 12] One pragmatic strategy has been the provision of methadone maintenance therapy within the prison system in an effort to reduce demand for illicit opiates. Unfortunately, however, this strategy is likely to be insufficient (e.g., for those who are primarily stimulants users – a growing population), and it is noteworthy that there was still illicit opiate use occurring in the prison where the patient described in this report initiated his opiate use, even though methadone was available there. While the expansion and evaluation of addiction treatment measures in prisons is an immediate priority, the burgeoning levels of incarceration of drug users and the rates of ongoing illicit drug use among incarcerated individuals indicate that additional strategies must be considered. [1–4, 6–9] This implies that alternative programs to incarceration, such as the treatment of addiction in the community, may be more effective at reducing the health and social harms and economic costs of illicit drug use. [13, 14] Expanded addiction services in prison should therefore be coupled with expansion and evaluation of community diversion programs for non-violent drug offenders.
In this brief report, we have described a case of an individual initiating opiate use and developing dependency to opiates within a Canadian prison. Unfortunately, this case is not unique,  and the concerns it raises are relevant to the many illicit drug users who do not use opiates in the community but risk initiating opiate use (including intravenous use) when incarcerated. And although the risks of HIV transmission in prison have been widely reported, the implications of initiation of illicit drug addiction in prison have not received adequate attention by public health and correctional policy-makers. Effective practical interventions are needed to address this concern, including expansion of strategies involving expanded community diversion programs for non-violent drug offenders. These deserve particular attention, given their potential to reduce HIV risk for current injectors who are incarcerated and to reduce the prevalence of initiation of illicit drug use (and, potentially, injecting) in the non-addicted inmate population.
- Drucker E: Population impact of mass incarceration under New York's Rockefeller drug laws: an analysis of years of life lost. J Urban Health. 2002, 79: 434-435.PubMed CentralView ArticlePubMedGoogle Scholar
- Centers for Disease Control and Prevention (CDC): Tuberculosis outbreaks in prison housing units for HIV-infected inmates-California, 1995–1996. MMWR Morb Mortal Wkly Rep. 1999, 48: 79-82.Google Scholar
- Wolfe MI, Xu F, Patel P, O'Cain M, Schillinger JA, St Louis ME, Finelli L: An outbreak of syphilis in Alabama prisons: correctional health policy and communicable disease control. Am J Public Health. 2001, 91: 1220-1225.PubMed CentralView ArticlePubMedGoogle Scholar
- Taylor A, Goldberg D, Emslie J, Wrench J, Gruer L, Cameron S, Black J, Davis B, McGregor J, Follett E: Outbreak of HIV infection in a Scottish prison. BMJ. 1995, 310: 289-292.PubMed CentralView ArticlePubMedGoogle Scholar
- Wood E, Li K, Small W, Montaner JS, Schechter MT, Kerr T: Recent incarceration independently associated with syringe sharing by injection drug users. Public Health Rep. 2005, 120: 150-156.PubMed CentralPubMedGoogle Scholar
- Yirrell DL, Robertson P, Goldberg DJ, McMenamin J, Cameron S, Leigh Brown AJ: Molecular investigation into outbreak of HIV in a Scottish prison. BMJ. 1997, 314: 1446-1450.PubMed CentralView ArticlePubMedGoogle Scholar
- Estebanez PE, Russell NK, Aguilar MD, Beland F, Zunzunegui MV: Women, drugs and HIV/AIDS: results of a multicentre European study. Int J Epidemiol. 2000, 29: 734-743. 10.1093/ije/29.4.734.View ArticlePubMedGoogle Scholar
- Dolan KA, Wodak A: HIV transmission in a prison system in an Australian state. Med J Aust. 1999, 171: 14-17.PubMedGoogle Scholar
- Estebanez P, Zunzunegui MV, Aguilar MD, Russell N, Cifuentes I, Hankins C: The role of prisons in the HIV epidemic among female injecting drug users. AIDS Care. 2002, 14: 95-104.View ArticlePubMedGoogle Scholar
- Small W, Kain S, Laliberte N, Schechter MT, O'Shaughnessy MV, Spittal PM: Incarceration, addiction, and harm reduction: inmates' experience injecting drugs in prison. Subst Use Misuse. 2005, 40: 831-843. 10.1081/JA-200030795.View ArticlePubMedGoogle Scholar
- Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry JV: Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ. 2000, 321: 78-82. 10.1136/bmj.321.7253.78.PubMed CentralView ArticlePubMedGoogle Scholar
- Dolan KA: Can hepatitis C transmission be reduced in Australian prisons?. Med J Aust. 2001, 174: 378-379.PubMedGoogle Scholar
- Rydell CP, Caulkins JP, Everingham SE: Enforcement or treatment? modeling the relative efficacy of alternatives for controlling cocaine. Oper Res. 1996, 44: 687-695.View ArticleGoogle Scholar
- Wood E, Tyndall MW, Spittal PM, Li K, Anis AH, Hogg RS, Montaner JSG, O'Shaughnessy MV, Montaner JSG, Schechter MT: Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. Can Med Assoc J. 2003, 168: 165-169.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.